Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Leukemia, Myeloid, Acute 54Myelodysplastic Syndromes 47Leukemia 36Lymphoma, Non-Hodgkin 34Lymphoma 32Breast Neoplasms 29Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Central Nervous System Neoplasms 21Hodgkin Disease 19Hematologic Neoplasms 19Neuroblastoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Burkitt Lymphoma 15Multiple Myeloma 14Medulloblastoma 14Leukemia, Myeloid, Accelerated Phase 13Leukemia, Biphenotypic, Acute 13Brain Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Blast Crisis 12Graft vs Host Disease 11Congenital Abnormalities 11Myeloproliferative Disorders 10Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Follicular 10Dendritic Cell Sarcoma, Interdigitating 10Astrocytoma 10Anemia, Refractory, with Excess of Blasts 10Recurrence 9

Interventions

Transplantation Conditioning 1Thiotepa 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × High Risk Myeloid Malignancies × Thiotepa × Clear all
NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡